Personalis (NASDAQ:PSNL) Raised to “Hold” at Zacks Research

Personalis (NASDAQ:PSNL) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday, Zacks reports.

Several other research firms have also issued reports on PSNL. Lake Street Capital lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price for the company. in a report on Monday, July 20th. TD Cowen restated a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. BTIG Research raised their price objective on Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a research report on Monday, July 20th. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $14.54.

Personalis Price Performance

Shares of Personalis stock opened at $16.60 on Monday. Personalis has a 1 year low of $4.95 and a 1 year high of $18.89. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -15.23 and a beta of 2.31. The company has a 50-day moving average of $14.68 and a 200 day moving average of $10.41.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The business had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. On average, equities analysts anticipate that Personalis will post -1.07 EPS for the current year.

Insider Activity

In other news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the sale, the chief executive officer owned 235,986 shares in the company, valued at $3,558,668.88. This represents a 29.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18. Following the sale, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at $2,620,618.94. This trade represents a 20.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 256,233 shares of company stock valued at $3,568,236 over the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd boosted its stake in Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Personalis in the 4th quarter worth $31,000. Legal & General Group Plc bought a new stake in shares of Personalis in the 2nd quarter worth $30,000. Quantbot Technologies LP purchased a new position in shares of Personalis in the second quarter worth $69,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares during the last quarter. 61.91% of the stock is owned by institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.